Biotech stock Cardiol Therapeutics Inc. (TSX:CRDL | OTCQX:CRTPF | FSE:CT9) has enrolled its first patient in the LANCER trial. This is a Phase II/III Outcomes Trial evaluating high-risk patients hospitalized with Covid-19 who have a prior history of, or risk factors for, cardiovascular disease. Cardiol broke the news of its first participant in a press release dated April 28.
Dr. Andrew Hamer, Chief Medical Officer of Cardiol Therapeutics said:
“There is compelling evidence that inflammation plays a fundamental role in the development and progression of heart disease. I am excited to see the initiation of the LANCER trial which will provide a unique opportunity to explore the anti-inflammatory and cardioprotective properties of CardiolRx in COVID-19 patients who are at high risk for major cardiovascular complications.”
Photographer: Robina Weermeijer | Source: Unsplash
Helping fight the effects of Covid-19
The tragedy of Covid-19 continues to shroud the world in its devastating grip. Therefore, any chance of respite is warmly embraced. This trial by Cardiol Therapeutics hopes to prove that its proprietary drug CardiolRx has a protective effect in preventing cardiovascular complications in Covid-19 patients with pre-existing or risk factors for cardiovascular disease. These cardiovascular complications can include acute myocardial infarction, cardiac arrhythmias, myocarditis, stroke, and heart failure.
CardiolRx is an oral formulation containing cannabidiol (aka CBD), a chemical found in the cannabis sativa plant. The therapeutic and anti-inflammatory properties of cannabidiol are progressively being applauded.
CardiolRx is an oral formulation containing cannabidiol
CardiolRx is not Cardiol’s only CBD product. The company commercialized Cortalex, a pharmaceutically produced CBD formulation developed for the $575 million medicinal cannabidiol market in Canada.
GET OUR SPECIAL REPORT ON CARDIOL’S REVOLUTIONARY TREATMENT AND HOW EARLY INVESTORS COULD PROFIT.
A randomized, double-bind study
The LANCER trial has been approved by the U.S. Food and Drug Administration (FDA). It will test the efficacy of CardiolRx in a Phase II/III stage in preventing cardiovascular complications in those participants. It’s a randomized, double-blind, placebo-controlled study.
In its full capacity it will assess the efficacy and safety of the drug in 422 hospitalized patients. Each of whom will have a confirmed diagnosis of Covid-19 in addition to pre-existing or significant risk factors of cardiovascular disease.
This study splits the patients into two groups; active and placebo. The outcomes being recorded during a 28-day-period include all-cause mortality, requirement for ICU admission and/or ventilatory support, along with cardiovascular complications. These further complications comprise the development of heart failure, acute myocardial infarction, myocarditis, stroke, or new sustained or symptomatic arrhythmia.
The outcome of contracting Covid-19 varies from person to person. And no-one can predict how they’ll respond to the virus. That’s because it ranges from causing little to no symptoms, to severe symptoms, to death.
Severe complications such as bilateral pneumonia, or acute respiratory symptoms can be exacerbated by advanced age (over 64) or the prior presence of cardiovascular disease.
An exciting biotech growth stock
The company has a $148m market cap and its share price has risen 35% year-to-date. If CardiolRx proves to be successful in reducing severe cardiovascular symptoms in Covid-19 positive patients, it’s sure to have a major impact on the valuation of Cardiol Therapeutics.
That’s because any therapy that can limit the severity of this destructive disease is going to be in high demand. It would make an immensely positive difference to many lives, thereby proving the long-term viability of Cardiol Therapeutics as a strong investment.
Successful trial results may also lead to supporting a new drug application. In any case, it will provide the collation of invaluable clinical data providing insight into the therapeutic potential of CardiolRx.
Furthermore, chronic heart failure is understood to cost the U.S. healthcare system over $30 billion. Therefore, anything that reduces this burden is sure to be welcomed.
An independent committee of international experts in inflammatory heart disease is overseeing the LANCER trial. And it should be completed later this year. If CardiolRx proves effective, it’s likely to result in an emergency use authorization for the treatment of any Covid-19 patients who would have qualified for enrolment in the LANCER trial.
Get our FREE IN-DEPTH REPORT to discover the wealth generating potential of investing in Cardiol Therapeutics!
IMPORTANT NOTICE AND DISCLAIMER
Paid Advertisement
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of forty thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
Changes in Share Trading and Price
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
No Offer to Sell or Buy Securities
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
Information
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
No Financial Advice
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
Forward Looking Statements
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
Indemnification/Release of Liability
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
Terms of Use and Disclaimer
By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.
Intellectual Property
All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than Valuethemarkets.com.
Authors: ValueTheMarkets
Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production of this piece by the company or companies mentioned above.
